Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index; 5 of the 31 sources its claims cite were checked for support.
Abstract
Inactivated poliovirus vaccine (IPV) may be used in mass vaccination campaigns during the final stages of polio eradication. It is also likely to be adopted by many countries following the coordinated global cessation of vaccination with oral poliovirus vaccine (OPV) after eradication. The success of IPV in the control of poliomyelitis outbreaks will depend on the degree of nasopharyngeal and intestinal mucosal immunity induced against poliovirus infection. We performed a systematic review of studies published through May 2011 that recorded the prevalence of poliovirus shedding in stool samples or nasopharyngeal secretions collected 5-30 days after a "challenge" dose of OPV. Studies were combined in a meta-analysis of the odds of shedding among children vaccinated according to IPV, OPV, and combination schedules. We identified 31 studies of shedding in stool and four in nasopharyngeal samples that met the inclusion criteria. Individuals vaccinated with OPV were protected against infection and shedding of poliovirus in stool samples collected after challenge compared with unvaccinated individuals (summary odds ratio [OR] for shedding 0.13 (95% confidence interval [CI] 0.08-0.24)). In contrast, IPV provided no protection against shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59-1.11]) or when given in addition to OPV, compared with individuals given OPV alone (summary OR 1.14 [95% CI 0.82-1.58]). There were insufficient studies of nasopharyngeal shedding to draw a conclusion. IPV does not induce sufficient intestinal mucosal immunity to reduce the prevalence of fecal poliovirus shedding after challenge, although there was some evidence that it can reduce the quantity of virus shed. The impact of IPV on poliovirus transmission in countries where fecal-oral spread is common is unknown but is likely to be limited compared with OPV.
Overview
CoChat Summary
TL;DR
Systematic review and meta-analysis of poliovirus challenge studies found that OPV strongly reduces fecal poliovirus shedding after challenge, whereas IPV alone or added to OPV does not significantly reduce the prevalence of shedding. IPV may reduce the quantity and duration of virus shed, but evidence for nasopharyngeal mucosal protection was insufficient.
Key findings
- OPV-vaccinated individuals were protected against poliovirus shedding in stool after challenge compared with unvaccinated individuals: summary OR 0.13 (95% CI 0.08–0.24).
- IPV provided no significant protection against stool shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59–1.11]) or when added to OPV compared with OPV alone (summary OR 1.14 [95% CI 0.82–1.58]).
- Direct comparison of OPV versus IPV schedules favored OPV: overall OR 0.15 (95% CI 0.08–0.27).
- Five studies quantifying shedding found a 63%–91% (absolute 0.43–1.0 log10) reduction in mean quantity of poliovirus shed in stool among IPV-vaccinated compared with unvaccinated children; two of three studies examining duration found shorter shedding, and one study suggested combined quantity and duration reductions could reduce total virus shed by approximately 95%.
- There were insufficient studies of nasopharyngeal shedding to draw a conclusion.
Methods
- Systematic review of studies published through May 2011 identified via PubMed and Web of Knowledge, plus citation searching; 1,981 articles plus 6 additional studies were screened, yielding 31 stool-shedding studies and 4 nasopharyngeal-shedding studies meeting inclusion criteria.
- Inclusion required recording prevalence of vaccine poliovirus shedding in stool or nasopharyngeal samples collected 5–30 days after a challenge dose of live-attenuated poliovirus; exclusions included duplicate findings, immunocompromised individuals, fewer than 30 individuals, insufficient serotype/schedule/shedding data, or challenge more than 5 years after vaccination.
- Meta-analysis compared odds of shedding across vaccination categories—unvaccinated, trivalent OPV only, IPV only, and combined schedules—using fixed- or random-effects models according to heterogeneity, implemented in R with the rmeta package.
Limitations
- The paper states there were insufficient nasopharyngeal shedding studies to draw conclusions, and that few samples were positive with insufficient power to compare vaccination histories.
- The paper reports significant heterogeneity in some meta-analyses from variable sample timing, number/timing of vaccine doses, laboratory procedures, and unmeasured factors such as enteric infections; there were insufficient studies for a formal meta-regression.
- The paper states there are no studies with adequate control populations investigating IPV impact on wild-type poliovirus transmission in areas with efficient fecal-oral transmission, and that challenge with high-titer Sabin poliovirus differs from natural wild-type exposure; the relationship between quantity shed and onward transmission is unknown.
- Evident from the text: only 18 studies were included in the meta-analyses comparing vaccination histories, and only one study compared serotype 2 shedding in OPV-only versus OPV/IPV individuals, so no summary OR was calculated for that comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Flow diagram showing included studies according to PRISMA guidelines [46]. The number of published articles identified by the given search term for initial screening and the resulting studies identified and included in the systematic review and meta-analysis are shown.](https://figures.cochat.ai/paper-figures/f7fa06a7c24446bdb28e75ad429edb87/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-1.jpg)
![Figure 2 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with unvaccinated individuals. Odds ratios (ORs) and 95% confidence intervals for individual studies are indicated by the boxes and grey lines. The summary odds ratio for each serotype is given by a diamond with the 95% confidence interval (CI) indicated by its width. The χ2 test for heterogeneity among studies was significant for serotypes 2 and 3 (p-values 0.33, <0.001, and 0.001 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). Details of the studies included are given in Table S1. *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/cdf5934daf6143bea94adeadb60a35a7/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-2.jpg)
![Figure 3 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV compared with unvaccinated individuals. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was not significant for any serotype (p-values 0.11, 0.47, and 0.07) or for the overall odds ratio (p-value 0.10). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/02e3301e07954edd96d8e51b7d7826c2/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-3.jpg)
![Figure 4 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with OPV compared with IPV. Labeling as for Figure 2. The χ2 test for heterogeneity among studies was significant for serotypes 1 and 3 (p-values<0.001, 0.79, and 0.01 for serotypes 1, 2, and 3, respectively) and for the overall odds ratio (p-value<0.001). *Ghendon et al. 1961 [17] compare vaccinated and unvaccinated children who were confirmed seropositive and seronegative, respectively.](https://figures.cochat.ai/paper-figures/02290bcc61df4f4bbcf19524c4472bc4/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-4.jpg)
![Figure 5 Relative odds of shedding vaccine poliovirus after challenge among individuals vaccinated with IPV in addition to OPV compared with individuals vaccinated with OPV only. Labeling as for Figure 2. The schedule indicates the number and type of OPV doses received by both groups and the number of doses of IPV that were added in the intervention group. In two studies, IPV was administered simultaneously with OPV at 6, 10, and 14 weeks (Modlin et al. 1997 [47] and du Chatelet et al. 2003 [48]), and in one study IPV was administered before and at the same time as OPV (schedule was IPV, IPV/OPV, OPV, OPV at 2, 4, 6, 15 months; WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines 1997 [49]). The χ2 test for heterogeneity among studies for serotypes 1 and 3 was not significant for each serotype (p-values 0.13 and 0.08) or for the serotypes combined (p-value 0.14).](https://figures.cochat.ai/paper-figures/f9e2423eecde4ebba5d508acc77f6bb4/systematic-review-of-mucosal-immunity-induced-by-oral-and-inactivated-poliovirus-figure-5.jpg)
Verification
Claims the paper makes
4 Valid · 1 Not valid · 19 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The impact of IPV in these studies is perhaps more likely to relate to local immunity induced by IPV through transudation of serum IgG rather than induction of a local secretory IgA response [7].”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Disputedcites [7] TM Herremans, 1999, Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus., J Immunol sourceExperimental — accuracy not yet measured
The Discussion says salivary IgG in IPV recipients was low or absent, suggesting it does not protect against mucosal poliovirus infection; any protective effect of circulating IgG remains untested. It instead attributes previously reported mucosal responses after IPV to prior priming with live virus and reports mucosal IgA responses after IPV boosting in previously OPV-vaccinated people. The proposed IgG-over-IgA explanation runs contrary to that account. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent evidence from India for waning intestinal immunity to poliovirus within a year of vaccination with OPV [38] and identification of wild-type polioviruses in stool samples from OPV immunized children [39] has generated interest in the potential for IPV to boost intestinal immunity among these children.”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Supportedcites [39] NC Grassly, 2010, Asymptomatic wild poliovirus infection in India among children previously immunized with oral poliovirus vaccine., J Infect Dis source
The Discussion reports that serotype 1 wild-type poliovirus was isolated from stool samples of children who reported receiving at least 10 OPV doses. This directly supports the identification attributed to this paper. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Five studies that quantified poliovirus shedding found a 63%–91% (or an absolute 0.43–1.0 log10) reduction in the mean quantity of poliovirus shed in stool samples collected from IPV vaccinated compared with unvaccinated children [5], [17]–[20] (Table S1).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
What the sources say
- Supportedcites [5] JL Henry, 1966, A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine., J Hyg (Lond) source
The ‘Amount of virus excreted after challenge’ section calculates mean virus content in feces and reports lower excretion in the killed-poliovaccine group than in the unvaccinated comparison group. This supports citing the paper as one of the five studies; the 63%–91% range describes the five studies collectively, not a result attributed to this paper alone. (LLM, conf=0.85)
- Not matchedcites [17]–[20]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The superior impact of OPV on intestinal mucosal immunity is confirmed by the meta-analysis of studies that directly compared schedules that exclusively used OPV or IPV (overall OR for OPV compared with IPV immunized children was 0.15 [0.08–0.27]).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, the prevalence of challenge poliovirus shedding was highly variable among studies, even for those that examined very similar vaccination schedules (Table S1).”
§ Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 49 claims and to verify the 3 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IPV does not induce sufficient intestinal immunity to be effective in the prevention of virus spread [63,67].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“OPV vaccination is effective in preventing the shedding of WPV in the stool after exposure, which suggests that OPV induces sufficient intestinal mucosal immunity against PV infection and helps in the prevention of virus transmission [63].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [63]
Experimental — accuracy not yet measured
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“Flow diagram showing included studies according to PRISMA guidelines”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Summary ORs and 95% confidence intervals were calculated on a log scale assuming either fixed effects or normally distributed random effects among studies according to the results of the x(2) test [44].”
MethodWang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Ogra, P. L., Karzon, D. T., Righthand, F., & MacGillivray, M. (1968) · New England Journal of Medicine · doi:10.1056/nejm196810242791701 · Cited by 397 · cited 2×
“In contrast, intramuscular injection of IPV induces serum antibodies but does not induce secretory IgA at the mucosal surfaces [3] and has a much more limited impact on the resistance of the intestine to infection [5].”
BackgroundBONE MARROW TRANSPLANTATION IN FIVE CHILDREN WITH SICKLE CELL ANAEMIA
Vermylen, C., Ninane, J., Fernandez Robles, E., & Cornu, G. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92239-8 · Cited by 196
Hovi, T., Huovilainen, A., Kuronen, T., Pöyry, T., Salama, N., Cantell, K., Kinnunen, E., Lapinleimu, K., Roivainen, M., Stenvik, M., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91566-7 · Cited by 186 · cited 1×
“Where importations of wild-type polioviruses to these countries have been documented, they have resulted in outbreaks ranging from a single case to over 100 cases of poliomyelitis [29–32].”
BackgroundFractional Doses of Inactivated Poliovirus Vaccine in Oman
Mohammed, A. J., AlAwaidy, S., Bawikar, S., Kurup, P. J., Elamir, E., Shaban, M. M. A., Sharif, S. M., van der Avoort, H. G. A. M., Pallansch, M. A., Malankar, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909383 · Cited by 172 · cited 1×
“determine market size and supply capacity [9–11].”
Alexander, J. P., Gary, H. E., & Pallansch, M. A. (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s176 · Cited by 170
Herremans, T. M. P. T., Reimerink, J. H. J., Buisman, A. M., Kimman, T. G., & Koopmans, M. P. G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.5011 · Cited by 149 · cited 3×
“The impact of IPV in these studies is perhaps more likely to relate to local immunity induced by IPV through transudation of serum IgG rather than induction of a local secretory IgA response [7].”
BackgroundResik, S., Tejeda, A., Lago, P. M., Diaz, M., Carmenates, A., Sarmiento, L., Alemañi, N., Galindo, B., Burton, A., Friede, M., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651611 · Cited by 146 · cited 1×
“determine market size and supply capacity [9–11].”
Inactivated poliovirus vaccine: Past and present experience
Murdin, A. D., Barreto, L., & Plotkin, S. (1996) · Vaccine · doi:10.1016/0264-410x(95)00211-i · Cited by 135 · cited 1×
“In northern European countries (France, Netherlands, Sweden, Finland, Iceland), IPV schedules have resulted in the eradication of wild-type polioviruses and protected against large outbreaks of paralytic disease for several decades [28].”
BackgroundPoliomyelitis outbreak in Israel in 1988: a report with two commentaries.
Slater, P. E., Costin, C., Yarrow, A., Ben-Zvi, T., Avni, A., Epstein, I., Orenstein, W. A., Morag, A., Handsher, R., Green, M. S., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)92705-m · Cited by 111 · cited 1×
“However, there is some evidence from Israel that IPV-using communities are more at risk compared with OPV-using communities [33].”
BackgroundWorld Health Organization Collaborative Study Group on Oral Poliovirus Vaccine (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.5.1097 · Cited by 110
Henry, J. L., Jaikaran, E. S., Davies, J. R., Tomlinson, A. J. H., Mason, P. J., Barnes, J. M., & Beale, A. J. (1966) · Journal of Hygiene · doi:10.1017/s0022172400040389 · Cited by 101 · cited 1×
“In contrast, intramuscular injection of IPV induces serum antibodies but does not induce secretory IgA at the mucosal surfaces [3] and has a much more limited impact on the resistance of the intestine to infection [5].”
BackgroundChapter 1 The Pathogenesis of Poliomyelitis: What We Don't Know
Nathanson, N. (2008) · Advances in Virus Research · doi:10.1016/s0065-3527(08)00001-8 · Cited by 95
Modlin, J. F., Halsey, N. A., Thoms, M. L., Meschievitz, C. K., Patriarca, P. A., & the Baltimore Area Polio Vaccine Study Group (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s228 · Cited by 93
Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa054960 · Cited by 90
WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s215 · Cited by 88
Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains
Laassri, M., Lottenbach, K., Belshe, R., Wolff, M., Rennels, M., Plotkin, S., & Chumakov, K. (2005) · The Journal of Infectious Diseases · doi:10.1086/498172 · Cited by 85 · cited 1×
“Three of these studies also examined the duration of shedding and two found a shorter period of shedding in IPV vaccinated children [17,19].”
BackgroundTrial of a Supplemental Dose of Four Poliovirus Vaccines
Sutter, R. W., Suleiman, A. J. M., Malankar, P., Al-Khusaiby, S., Mehta, F., Clements, G. B., Pallansch, M. A., & Robertson, S. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431103 · Cited by 84 · cited 1×
“We included challenge studies that compared shedding of challenge poliovirus across two or more vaccination schedules in a meta-analysis. Where stool samples were available for more than one time point, we used data from the sample taken closest to 7 days after challenge. For the purposes of the meta-analysis, schedul…”
MethodIsolation of epidemic poliovirus from sewage during the 1992–3 type 3 outbreak in the Netherlands
van der Avoort, H. G. A. M., Reimerink, J. H. J., Ras, A., Mulders, M. N., & van Loon, A. M. (1995) · Epidemiology and Infection · doi:10.1017/s0950268800052195 · Cited by 77
LIMITATION OF FECAL AND PHAEYNGEAL POLIOVIEUSEXCRETION IN SALK-VACCINATED CHILDREN
MARINE, W. M., CHIN, T. D. Y., & GRAVELLE, C. R. (1962) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120272 · Cited by 75 · cited 1×
“Three studies of wild-type poliovirus shedding in the nasopharynx after natural exposure during epidemics in the United States in 1956–1960 found a lower prevalence of shedding among children who had a history of vaccination with IPV [21–24].”
BackgroundWahid, R., Cannon, M. J., & Chow, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.10.5988-5995.2005 · Cited by 73 · cited 1×
“In addition, basic immunology research is required to better understand the mucosal immune response to both IPV and OPV, and in particular the adaptive cellular and innate components [36,37].”
BackgroundWaning Intestinal Immunity After Vaccination With Oral Poliovirus Vaccines in India
Grassly, N. C., Jafari, H., Bahl, S., Sethi, R., Deshpande, J. M., Wolff, C., Sutter, R. W., & Aylward, R. B. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis241 · Cited by 72
Self-citationInterrupting the transmission of wild polioviruses with vaccines: immunological considerations.
(1994) · Europe PMC (PubMed Central) · Cited by 70
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper—Recommendations
Publication, W. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.023 · Cited by 64
(1961) · Acta Virologica · Cited by 62
Dowdle, W., Van Der Avoort, H., De Gourville, E., Delpeyroux, F., Desphande, J., Hovi, T., Martin, J., Pallansch, M., Kew, O., & Wolff, C. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00844.x · Cited by 61 · cited 1×
“an estimated median infectious dose for humans of about 10 median tissue culture infectious doses (TCID50) compared with about 10(3) for Sabin polioviruses [25].”
BackgroundPolio vaccines and polio immunization in the pre-eradication era: WHO position paper.
(2010) · PubMed · Cited by 61
Grassly, N. C., Jafari, H., Bahl, S., Durrani, S., Wenger, J., Sutter, R. W., & Bruce Aylward, R. (2010) · The Journal of Infectious Diseases · doi:10.1086/651952 · Cited by 50
Self-citationdu Châtelet, I. P., Merchant, A. T., Fisher‐Hoch, S. P., Luby, S. P., Plotkin, S. A., Moatter, T., Agboatwalla, M., & Cormick, J. B. M. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00523-6 · Cited by 48
Immunisation against poliomyelitis: moving forward
Ehrenfeld, E., Glass, R. I., Agol, V. I., Chumakov, K., Dowdle, W. R., John, T. J., Katz, S. L., Miller, M. D., Breman, J. G., Modlin, J. F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60597-8 · Cited by 44 · cited 1×
“tiveness are compromised [12].”
The case for global eradication of poliomyelitis.
(1987) · Europe PMC (PubMed Central) · Cited by 43
Immunization with Live Attenuated Poliovirus Vaccine
KRUGMAN, S. (1961) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1961.04020020025005 · Cited by 38 · cited 1×
“These were: 1) study records the prevalence of vaccine poliovirus shedding in stool or nasopharyngeal samples collected after administration of a challenge dose of live-attenuated poliovirus; 2) samples collected 5–30 days after challenge (shedding of virus up to 4 days after challenge was excluded, because it has bee…”
Immunisation against polioviruses in developing countries.
John, T. J. (1993) · Reviews in Medical Virology · doi:10.1002/rmv.1980030305 · Cited by 37 · cited 2×
“control populations that investigate the impact of IPV on wild-type poliovirus transmission in such areas [13].”
BackgroundKurstak, E. (1993) · Springer eBooks · doi:10.1007/978-3-7091-9278-8 · Cited by 37
Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion.
Valtanen, S., Roivainen, M., Piirainen, L., Stenvik, M., & Hovi, T. (2000) · The Journal of Infectious Diseases · doi:10.1086/315684 · Cited by 36
Troy, S. B., Ferreyra-Reyes, L. D., Huang, C., Mahmud, N., Lee, Y.-J., Canizales‐Quintero, S., Flaster, H. V., Báez-Saldaña, R., García‐García, L., & Maldonado, Y. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02524-10 · Cited by 33
Poliomyelitis epidemic in the Netherlands, 1978.
Bijkerk, H. (1979) · PubMed · Cited by 30
Davis, D. C., Lipson, M. J., Carver, D. H., Melnick, J. L., & Robbins, F. C. (1958) · Pediatrics · doi:10.1542/peds.22.1.33 · Cited by 29 · cited 1×
“Three studies of wild-type poliovirus shedding in the nasopharynx after natural exposure during epidemics in the United States in 1956–1960 found a lower prevalence of shedding among children who had a history of vaccination with IPV [21–24].”
BackgroundEpidemiological events surrounding a paralytic case of poliomyelitis in Sweden.
(1979) · Europe PMC (PubMed Central) · Cited by 29
Wehrle, P. F., Reichert, R., Carbonaro, O., & Portnoy, B. (1958) · PEDIATRICS · doi:10.1542/peds.21.3.353 · Cited by 28
Oostvogel, P. M., Rumke, H. C., Conyn–van Spaendonck, M. A. E., van der Avoort, H. G. A. M., Leeuwenburg, J., & van Loon, A. M. (2001) · The Journal of Infectious Diseases · doi:10.1086/324327 · Cited by 26 · cited 1×
“Furthermore, asymptomatic wild poliovirus shedding has been detected among IPV vaccinated children during outbreaks in these European countries, albeit at lower frequencies than in unvaccinated children [32,34].”
BackgroundKrieg, C., Maier, R., & Meyerhans, A. (2004) · Journal of General Virology · doi:10.1099/vir.0.79919-0 · Cited by 24 · cited 1×
“individuals who have been previously exposed to live-attenuated or wild-type poliovirus [6,7].”
BackgroundInactivated and live, attenuated poliovirus vaccines: mucosal immunity.
Sutter, R. W., & Patriarca, P. A. (1993) · Measles and Poliomyelitis · doi:10.1007/978-3-7091-9278-8_23 · Cited by 23 · cited 2×
“Using data from one of these studies [17], it has been noted that the combined reduction in both the quantity and duration of vaccine poliovirus shedding would reduce the total amount of poliovirus shed during the course of an infection by approximately 95% [15].”
BackgroundMethodInactivated poliovirus vaccine following oral poliovirus vaccine cessation.
(2006) · PubMed · Cited by 21
Wehrle, P. F., Carbonaro, O., Day, P. A., Whalen, J. P., Reichert, R., & Portnoy, B. (1961) · PubMed · Cited by 14
Enders, G., & Siegert, R. (1961) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1113045 · Cited by 8
Wehrle, P. F., Carbonaro, O., Day, P. A., Whalen, J. P., Reichert, R., & Portnoy, B. (1961) · Pediatrics · doi:10.1542/peds.27.5.762
Research works printed but not linked: 1
- G Enders-Ruckle, 1961, [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)]., Dtsch Med Wochenschr, 86, 1999
Cited by
Human gut-associated lymphoid tissues (GALT); diversity, structure, and function
Mörbe, U. M., Jørgensen, P. B., Fenton, T. M., von Burg, N., Riis, L. B., Spencer, J., & Agace, W. W. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00389-4 · Cited by 424
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
Insidious reintroduction of wild poliovirus into Israel, 2013
Anis, E., Kopel, E., Singer, S. R., Kaliner, E., Moerman, L., Moran-Gilad, J., Sofer, D., Manor, Y., Shulman, L. M., Mendelson, E., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.38.20586 · Cited by 162
“Ongoing national supplementary immunisation activity A supplementary immunisation activity using bivalent OPV [14,15] was initiated in the Southern district on 5 August 2013 and has been expanded nationally since 18 August, with the objective of rapidly interrupting WPV1 transmission across the country, particularly i…”
MethodKwon, K.-C., Verma, D., Singh, N. D., Herzog, R., & Daniell, H. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.005 · Cited by 150
Klapsa, D., Wilton, T., Zealand, A. M., Bujáki, E., Saxentoff, E. V., Troman, C. M., Shaw, A., Tedcastle, A. B., Majumdar, M., Mate, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01804-9 · Cited by 150
Self-citation
Metadata
- Authors
- Hird, T. R., & Grassly, N. C.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Grassly, Nicholas C.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-19
- Volume
- 8
- Issue
- 4
- Pages
- e1002599
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3330118
- OpenAlex
- W1971110767
- Cited by
- 221
- References
- 55
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 17 · 2019: 11 · 2018: 18 · 2017: 22 · 2016: 18 · 2015: 20 · 2014: 21 · 2013: 11 · 2012: 2
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- inactivated poliovirus vaccine, oral polio vaccine, mucosal immunity, intestinal immunity, polio eradication, vaccine challenge, fecal-oral transmission, poliomyelitis control
- MeSH terms
- Animals, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Virus Shedding, Poliovirus, Immunity, Mucosal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.